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Abstract 
Purpose: To evaluate paeoniflorin (PF) as a possible protective agent against liver fibrosis and its likely 
mechanisms of action.  
Methods: A rat model of liver fibrosis was induced by carbon tetrachloride (CCl4) injection. Liver 
damage was determined by serum levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) activities. The hydroxyproline content of proteins was measured as an indirect 
way of assessing collagen deposition. TGF-β1 levels and TGF-β/Smad signaling pathway-related genes 
and proteins were analyzed by quantitative polymerase chain reaction (qPCR) assay and Western blot 
assay. 
Results: After PF administration, serum ALT and AST levels were significantly (p < 0.01) reduced by 
34.9 and 37.6 %, respectively. Collagen deposition was also significantly (p < 0.01) reduced by 31.0 %. 
Hepatic stellate cell activation was significantly inhibited, as evidenced by suppressed α-SMA 
expression. PF inhibited phospo-Smad 2/3 by elevating Smad 7 level. 
Conclusion: PF alleviates CCl4-induced liver fibrosis in a dose-dependent manner probably by 
restoring the balance between activated Smad 2/3 and Smad7. Thus, PF might be a source of a novel 
anti-fibrotic agent. 
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Hepatic fibrosis is a major disease condition with 
severe morbidity. Hepatitis B and C virus 
infections, together with helminthic infection and 
biliary obstruction are the dominant causes of 
liver fibrosis [1]. Hepatic stellate cells (HSCs) 
play a pivotal role in the development of liver 
fibrosis. When activated, HSCs assume 
myofibroblast phenotype, resulting in rapid 
proliferation and massive collagen synthesis with 
attendant excessive extracellular matrix 
deposition. The collagen deposition could be 
degraded, thereby reversing the processes 
leading to the development of fibrosis, as 
evidenced in recent studies [2]. However, there is 
as at now no available therapeutic modality for 
preventing and/or effectively managing this 
condition. Therefore, there is urgent need to 
identify anti-fibrotic agents and to develop novel 
therapeutic approaches in the field of liver 
fibrosis management. 
 
Cortex moutan is commonly used in Traditional 
Chinese Medicine for treating hepatic disorders. 
Paeoniflorin (PF), isolated from Corte moutan, is 
a major bioactive compound with anti-
inflammatory and immune-regulatory effects 
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[3,4]. The anti-fibrotic effect of PF has been 
studied on both pulmonary [5,6] and renal 
interstitial fibrosis [7]. Studies of the effect of 
PF’on Schistosomiasis japonica-induced liver 
fibrosis have also been carried out [8,9]. 
 
The present study was aimed at examining the 
possible anti-fibrotic effect of PF in the liver and 




Chemicals and regents 
 
Paeoniflorin (PF) (C23H28O11, MW: 480.47, purity 
≥ 98 %) was purchased from Nanjing Ze-lang 
Biotechnology Inc. (Nanjing, China). Other 
chemicals were products of Sigma-Aldrich (St. 
Louis, USA). 
 
Animals and CCl4-induced liver fibrosis 
model 
 
Fifty male Sprague-Dawley rats (weighing 180-
220 g) obtained from the Animal Center of 
Nantong University (Nantong, China), were used 
for this study. They were maintained on rat chow 
and water ad libitum while being acclimatized. 
After acclimatization for 7 days, rats were divided 
randomly into five experimental groups of 10 rats 
each: group1, the normal control; group 2, the 
negative control exposed to CCL4 only; group 3, 
CCL4 + 50 mg PF/kg /day; group 4, CCL4 + 
100mg PF/kg/day and group 5, CCL4 + 200 mg 
PF/kg/day. Liver fibrosis was induced as 
previously described, with CCl4 (30 % v/v diluted 
with corn oil) injection, twice a week for eight 
consecutive weeks [10]. Rats in the normal 
control group received equivalent volume of corn 
oil (CCL4 vehicle), at the same frequency in 
which CCL4 was administered to the test rats. 
The study protocol was approved by the local 
Ethical Committee of Changzhi Medical College 
(CZMC 2015/23) and the rats were treated in line 
with “National Research Council for Animal Care” 
[11]. 
 
Liver function assay 
 
The rats were sacrificed, and blood samples 
were collected and centrifuged after clotting 
(3000 g, 4 °C). Serum AST and ALT were 
determined by automated analyzer (Roche, 
Indianapolis, USA). 
 
Quantitative polymerase chain reaction 
(qPCR) assay 
 
qPCR was performed with SsoFast EvaGreen 
Supermix (Bio-Rad, Hercules, USA). Primers 
were purchased from Sangon Biotechnology Inc. 
(Shanghai, China). These were: Col1α1 
(Forward: 5’-ACTCAGCCGTCTGTGCCTCA-3’; 
Reverse: 5’-GGAGGCCTCGGTGGACATTA-3’); 
α-SMA (Forward: 5’-CGAGAGGACGTTGTTAG 
CATAGAG-3’; Reverse: 5’-GGGCATCCACGAA 
ACCA-3’) and GAPDH (Forward: 5’-
AGTTCAACGGCACAGTCAAG-3’; Reverse: 5’-
TACTCAGCACCAGCATCACC-3’). The fold 
change in target gene expression was analyzed 




Rats were sacrificed and, the livers excised and 
hydrolyzed with the hydrolyzing solution (1 mL) 
at 95 °C for 20 min in water. The content of 
hydroxyproline in the supernatant was analyzed 
by specific kit (Nanjing Jian-cheng, Nanjing, 
China), and was expressed as μg hydroxyproline 
/g liver. 
 
Western blot assay 
 
Western blot was conducted as described 
previously [12] with primary antibodies specific 
for α-smooth muscle actin (SMA), Smad 2/3, 
Smad 7, phospho-Smad 2/3 and GAPDH (Santa 
Cruz Biotechnology, Santa Cruz,USA). 
 
Enzyme-linked immunosorbent assay (ELISA) 
 
Rats were sacrificed and blood samples were 
collected, allowed to clot and centrifuged (3000 
g, 4 °C). Serum TGF-β1 level in the supernatant 
was determined by specific ELISA kit (R&D, 




All the studies were performed in triplicate and 
data are presented as mean ± S.D. One-way 
ANOVA followed by Dunnett’s test was 
performed using SPSS version 19. P < 0.05 was 




Effect of PF on CCl4-induced liver damage 
 
The results of the effect of PF on CCL4- induced 
liver injury are shown in Figure 1. The serum of 
rats treated with CCl4 only (the negative control 
group) had elevated ALT and AST activities 
compared to the normal control (3.15- and 2.96-
fold, respectively). PF (100 and 200 mg/kg) 
treatment significantly reduced serum levels of 
both enzymes relative to the CCL4 only group of 
rats. 
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            Figure 1: Serum levels of ALT (A) and AST (B). **p < 0.01, *p < 0.05 
 
Effect of PF on collagen type I expression 
 
Collagen type I is dominantly expressed as the 
extracellular matrix in fibrotic liver. The results of 
the analysis of the effect of PF on its 
biosynthesis are presented in Figure 2. The 
production of the mRNA of Col1a1, which is 
translated to give the α chain of collagen type I, 
was elevated 2.62-folds compared to the 
negative control group. PF (100 and 200 
mg/kg/d) treatment significantly inhibited the 





Figure 2: Expression of the mRNA of Col1a1 
**p < 0.01, *p < 0.05 
 
Effect of PF on collagen deposition 
 
Hydroxyproline content is a common biomarker 
for assessing the severity of collagen deposition 
and hence is a test for liver fibrosis. As shown in 
Figure 3, PF (100 and 200 mg/kg) significantly 
reduced CCl4-induced liver fibrosis as evidenced 
by the low level of hydroxyproline (reduced by 
13.2 and 31.0% respectively). 
 
 
Figure 3: Rat liver hydroxyproline level 
**p < 0.01, *p < 0.05 
 
Effect of PF on HSCs activation 
 
α-SMA is a typical marker for activated 
myofibroblast-like HSCs. As the results 
presented in Figure 4 show, α-SMA expressions 
were significantly decreased in a dose-
dependent manner due to PF treatment, when 
compared to the negative control. Thus HSCs 
activation was partially suppressed. 
 
Effect of PF on TGF-β1 expression 
 
TGF-β1 plays a central role in activation of HSCs 
which culminates in liver fibrosis. As shown in 
Figure 5, TGF-β1 level was significantly elevated 
in rats treated only with CCl4. PF (100 and 200 
mg/kg/d) significantly decreased TGF-β1 
expression by 19.5 and 25.6 %, respectively, 
relative to fibrotic rats (group 2). 
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Figure 4: Expression of α-SMA mRNA (A) and its protein levels (B) 
 **p < 0.01, *p < 0.05 
 
 
Figure 5: Effect of PF on serum TGF-β1 level 
**p < 0.01, *p < 0.05 
 
 
Figure 6: Western blots of TGF-β/Smad signaling 
pathway-associated proteins 
 
Effect of PF on TGF-β/Smad signaling 
pathway 
 
As shown in Figure 6, phosphor.-Smad 2/3 level 
was markedly increased in the group of rats 
treated with only CCl4.when compared with the 
normal control value. In the group of rats 
exposed to carbon tetrachloride and the higher 
doses of PF, there were remarkable reductions in 
phosphor-Smad 2/3 levels. In the CCl4-only 
group, there was corresponding reduction in 
inhibitory Smad 7 level which was partially 
reversed after PF treatment. This observation 
suggests that reversal of liver level of inhibitory 
Smad 7 is likely to be the underlying mechanism 




It is currently believed that liver fibrosis could be 
reversed by collagen degradation. However, 
there is as at now no therapeutic agent(s) for 
such reversal. This study has revealed that PF 
isolated from Cortex moutan, could alleviate 
CCl4-induced hepatic fibrosis, as evidenced by 
lower ALT and AST levels and hydroxyproline 
content. The expression of α-SMA both in form of 
mRNA and protein product was also suppressed 
by PF administration in a dose-dependent 
manner. This indicates that the HSCs were 
activated. Investigation of TGF-β/Smad signaling 
pathway and the findings appear to suggest that 
PF inhibited HSCs activation by up -regulating 
Smad 7 expression, and by so doing mitigated 
CCl4-induced liver fibrosis. 
 
The anti-fibrotic effects of Paeonia lactiflora and 
Astragalus membranaceus extract on CCl4-
induced rat liver fibrosis has been reported 
previously [13]. However, the bioactive agent(s) 
in the extracts with anti-fibrotic effect has 
remained unclear. It does appear, based on the 
findings in this study that PF might be the major 
phytochemical entity in Paeonia lactiflora and 
Astragalus membranaceus extracts responsible 
for the anti-fibrotic bioactivity. This views is 
supported by the fact that it had similar effects on 
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both pulmonary [5,6] and renal interstitial fibrosis 
[7]. 
 
The activation of fibroblast HSCs is one of the 
central events in the fibrotic process. Activated 
HSCs exhibit a myofibroblast-like phenotype with 
positive α-SMA expression and excessive 
collagen secretion [2]. Among the central events, 
TGF-β1 is a key mediator that has been given 
considerable attention by a sizable number of 
research scientists. The chronic chemical 
assaults in the liver cause the mobilization and 
activation of macrophages. Activated 
macrophage is the primary cell type of TGF-β1 
secretion. The autocrine of activated HSCs is 
another source of TGF-β1 with positive feedback 
control of the TGF-β/Smad signaling pathway 
[14]. In the current study, TGF-β1 was down-
regulated in a dose-dependent way after PF 
administration. The findings in this study could be 
attributed to the inhibition of both the 
macrophages and the autocrine of HSCs, as well 
as the anti-inflammatory effect of PF, which have 
been widely reported [3,15]. 
 
The in vitro effect of PF on TGF-β/Smad pathway 
has been reported previously, based on the 
induction of S. japonicum egg antigen which has 
the ability to induce liver fibrosis also [16]. 
Chronic assaults on the liver, whether from the 
egg antigen of S. japonicum or hepatitis B virus 
infection, contribute to the activation of TGF-
β/Smad pathway. Bound by TGF-β1, the TGF-β 
receptors can phosphorylate Smad 2/3. 
Phosphor-Smad 2/3 binds to Smad 4 and 
translocates to specific promoter region in the 
nucleus to induce collagen expression [17]. As 
an inhibitory molecule, the deletion of Smad7 
gene product accentuates CCl4-induced liver 
fibrosis [18]. In addition, overexpression of 
Smad7 attenuated TGF-β/Smad pathway in 
CCl4-induced liver fibrosis model [19]. Although 
the underlying mechanisms are well elucidated, 
the development of anti-fibrotic agents, which 
target TGF-β/Smad remains unexplored. In the 
current work, marked elevation of phosphor-
Smad 2/3 accompanied by down -regulation of 
Smad 7 as observed following exposure to CCl4, 
indicate that there was an imbalance between 
activated Smad 2/3 and Smad7. However, PF 
reversed the imbalance in a dose-dependent 
manner, and thus suppressed TGF-β/Smad 





The findings of the present work demonstrate 
that PF is a potential anti-fibrotic agent. Smad7 
induction and the consequent restoration of the 
balance between activated Smad 2/3 and Smad 
7, is the probable underlying mechanism by 
which PF alleviates liver fibrosis. PF could 
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